PL1658848T3 - Preparaty zawierające ekteinascydynę i disacharyd - Google Patents

Preparaty zawierające ekteinascydynę i disacharyd

Info

Publication number: PL1658848T3
Authority: PL; Poland
Prior art keywords: ecteinascidin; disaccharide; formulations
Prior art date: 2004-10-29

Application number

PL05077333T

Other languages

English (en)

Inventor

Salve Pilar Calvo

Barreira Maria Tobio

Bastiaan Nuijen

Jacob Hendrik Beijnen

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-29

Filing date

2005-10-12

Publication date

2007-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1658848(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-12 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2007-12-31 Publication of PL1658848T3 publication Critical patent/PL1658848T3/pl

Links

150000002016 disaccharides Chemical class 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 title 1
229960000977 trabectedin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL05077333T 2004-10-29 2005-10-12 Preparaty zawierające ekteinascydynę i disacharyd PL1658848T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62381304P	2004-10-29	2004-10-29
EP05077333A EP1658848B1 (en)	2004-10-29	2005-10-12	Formulations comprising ecteinascidin and a disaccharide

Publications (1)

Publication Number	Publication Date
PL1658848T3 true PL1658848T3 (pl)	2007-12-31

Family

ID=35432682

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05077333T PL1658848T3 (pl)	2004-10-29	2005-10-12	Preparaty zawierające ekteinascydynę i disacharyd

Country Status (36)

Country	Link
US (2)	US8895557B2 (pl)
EP (1)	EP1658848B1 (pl)
JP (1)	JP4268163B2 (pl)
KR (1)	KR101188691B1 (pl)
CN (2)	CN1823794A (pl)
AR (2)	AR051653A1 (pl)
AT (1)	ATE368461T1 (pl)
AU (1)	AU2005227421B2 (pl)
BR (1)	BRPI0517238B1 (pl)
CA (1)	CA2520979C (pl)
CY (1)	CY1107773T1 (pl)
DE (1)	DE602005001833T2 (pl)
DK (1)	DK1658848T3 (pl)
ES (1)	ES2290844T3 (pl)
GT (1)	GT200500314A (pl)
HN (1)	HN2005029978A (pl)
HR (1)	HRP20070374T3 (pl)
IL (1)	IL182776A (pl)
JO (1)	JO2464B1 (pl)
MX (1)	MXPA05011650A (pl)
MY (1)	MY139049A (pl)
NO (1)	NO328035B1 (pl)
NZ (1)	NZ554761A (pl)
PA (1)	PA8650801A1 (pl)
PE (2)	PE20100089A1 (pl)
PL (1)	PL1658848T3 (pl)
PT (1)	PT1658848E (pl)
RS (1)	RS50510B (pl)
RU (1)	RU2382647C2 (pl)
SI (1)	SI1658848T1 (pl)
SV (1)	SV2006002283A (pl)
TW (1)	TWI296523B (pl)
UA (1)	UA91032C2 (pl)
UY (1)	UY29183A1 (pl)
WO (1)	WO2006046079A1 (pl)
ZA (1)	ZA200703450B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164077A (en) *	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
MXPA02011319A (es) *	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) *	2000-11-06	2003-10-21	Pharma Mar Sa	Tratamentos antitumorais eficazes
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
PL368458A1 (pl) *	2001-10-19	2005-03-21	Pharmamar S.A.	Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka
GB0202544D0 (en) *	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
HRP20080598T3 (en) *	2003-11-13	2009-01-31	Pharma Mar	Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) *	2003-11-14	2005-06-02	Pharma Mar, S.A.	Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
WO2006005602A2 (en) *	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) *	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
EP1827500B1 (en) *	2004-10-26	2009-05-06	Pharma Mar S.A., Sociedad Unipersonal	Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de)	2004-10-29	2007-08-15	Pharma Mar Sa	Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
US20100267732A1 (en) *	2007-10-19	2010-10-21	Pharma Mar, S.A.	Prognostic Molecular Markers for ET-743 Treatment
US20100196272A1 (en) *	2009-01-30	2010-08-05	Neoprobe Corporation	Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
RS54648B1 (sr)	2010-11-12	2016-08-31	Pharma Mar S.A.	Kombinovana terapija sa antitumorskim alkaloidom
DK2701720T3 (en) *	2011-04-28	2017-10-09	Oncopeptides Ab	Lyophilized preparation with cytotoxic dipeptides
CN106853252B (zh) *	2015-12-09	2020-03-13	江苏恒瑞医药股份有限公司	曲贝替定药物组合物及其制备方法
CN106880592B (zh) *	2015-12-15	2021-04-06	江苏恒瑞医药股份有限公司	一种曲贝替定的纳米乳及其制备方法
CA3011527A1 (en) *	2016-02-04	2017-08-10	Jiangsu Hengrui Medicine Co., Ltd.	Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and method for manufacturing the same
KR102491180B1 (ko)	2017-04-27	2023-01-20	파르마 마르 에스.에이.	항종양 화합물
WO2020239478A1 (en)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectedin for treating sarcomas based on genomic markers
US20210169873A1 (en) *	2019-10-21	2021-06-10	RK Pharma Solutions LLC	Storage-stable ready-to-use injectable formulations of Trabectedin
PE20252386A1 (es) *	2019-11-21	2025-10-10	Pharma Mar Sa	Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
EP4353232A3 (en)	2020-04-15	2024-06-26	EVER Valinject GmbH	Composition comprising trabectedin and an amino acid
IL308389A (en) *	2021-05-19	2024-01-01	Pharma Mar Sa	Dosing regimens for acubactadine
US12303506B2 (en)	2022-01-20	2025-05-20	Extrovis Ag	Trabectedin composition
CN118236331A (zh) *	2022-12-22	2024-06-25	博瑞生物医药（苏州）股份有限公司	一种含卢比替定的药物组合物及其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4537883A (en)	1982-11-12	1985-08-27	Mead Johnson & Company	Lyophilized cyclophosphamide
EP0309477B1 (en) *	1986-06-09	1991-11-06	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5089273A (en) *	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en)	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en)	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
DE3635711A1 (de) *	1986-10-21	1988-04-28	Knoll Ag	5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) *	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5336669A (en) *	1991-12-10	1994-08-09	Erbamont, Inc.	Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
DE4242863A1 (de)	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5478932A (en)	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
GB9401447D0 (en)	1994-01-26	1994-03-23	Ciba Geigy Ag	Pharmaceutical compositions
US20040059112A1 (en) *	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
GB9508195D0 (en) *	1995-04-20	1995-06-07	Univ British Columbia	Novel biologically active compounds and compositions,their use and derivation
US5721362A (en)	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
US5985876A (en)	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
JP4562815B2 (ja)	1997-05-21	2010-10-13	ジェネンテック，インコーポレイテッド	トロンボポエチンの新規な投与
BR9909488B1 (pt)	1998-04-06	2011-02-08		ecteinascidinas semi-sintéticas e composição farmacêutica.
CA2331593C (en)	1998-05-11	2008-08-05	Pharma Mar, S.A.	Metabolites of ecteinascidin 743
JP2000081438A (ja)	1998-06-25	2000-03-21	Sekisui Chem Co Ltd	被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) *	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
MY164077A (en) *	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
GB9918178D0 (en)	2000-05-15	1999-10-06	Pharma Mar Sa	Synthetic methods
AR035842A1 (es) *	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
WO2001077115A1 (en)	2000-04-12	2001-10-18	Pharma Mar, S.A.	Antitumoral ecteinascidin derivatives
US7247892B2 (en) *	2000-04-24	2007-07-24	Taylor Geoff W	Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) *	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) *	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
JP2004506430A (ja) *	2000-08-11	2004-03-04	シティ・オブ・ホープ	Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
NZ525243A (en) *	2000-10-31	2005-01-28	Pharma Mar S	A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
CA2447553A1 (en)	2000-11-03	2002-05-23	President And Fellows Of Harvard College	Saframycins, analogues and uses thereof
BR0115162A (pt) *	2000-11-06	2003-10-21	Pharma Mar Sa	Tratamentos antitumorais eficazes
EE200300323A (et) *	2001-01-25	2003-10-15	Bristol-Myers Squibb Company	Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
WO2002064843A1 (en) *	2001-02-09	2002-08-22	The Regents Of The University Of California	Ecteinascidin family compounds: compositions and methods
MXPA03007989A (es)	2001-03-06	2003-12-04	Bristol Myers Squibb Co	Metodo y forma de dosificacion para tratamiento de tumores por administracion de tegafur, uracil, acido folinico, paclitaxel y carboplatin.
WO2002078678A2 (en)	2001-03-30	2002-10-10	Shire Biochem Inc.	Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
PL368458A1 (pl) *	2001-10-19	2005-03-21	Pharmamar S.A.	Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka
US20040019027A1 (en) *	2002-04-12	2004-01-29	Barry Forman	Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
HRP20080598T3 (en) *	2003-11-13	2009-01-31	Pharma Mar	Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) *	2003-11-14	2005-06-02	Pharma Mar, S.A.	Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
WO2005118584A2 (en)	2004-05-26	2005-12-15	Axys Pharmaceuticals, Inc.	Saframycin analogs as therapeutic agents in the treatment of cancer
WO2006005602A2 (en) *	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en)	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
EP1827500B1 (en) *	2004-10-26	2009-05-06	Pharma Mar S.A., Sociedad Unipersonal	Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de)	2004-10-29	2007-08-15	Pharma Mar Sa	Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
WO2006066183A2 (en)	2004-12-16	2006-06-22	Axys Pharmaceuticals, Inc.	Novel saframycin analogs as therapeutic agents
ES2361566T3 (es) *	2005-11-25	2011-06-20	Pharma Mar S.A., Sociedad Unipersonal	Uso de inhibidores de parp-1.
CA2652035A1 (en) *	2006-05-12	2007-11-22	Pharma Mar, S.A.	Anticancer treatments

2005
- 2005-10-12 AT AT05077333T patent/ATE368461T1/de active
- 2005-10-12 PL PL05077333T patent/PL1658848T3/pl unknown
- 2005-10-12 EP EP05077333A patent/EP1658848B1/en not_active Expired - Lifetime
- 2005-10-12 SI SI200530052T patent/SI1658848T1/sl unknown
- 2005-10-12 KR KR1020077012043A patent/KR101188691B1/ko not_active Expired - Lifetime
- 2005-10-12 DK DK05077333T patent/DK1658848T3/da active
- 2005-10-12 WO PCT/GB2005/050184 patent/WO2006046079A1/en not_active Ceased
- 2005-10-12 PT PT05077333T patent/PT1658848E/pt unknown
- 2005-10-12 NZ NZ554761A patent/NZ554761A/en not_active IP Right Cessation
- 2005-10-12 RS RSP-2007/0350A patent/RS50510B/sr unknown
- 2005-10-12 BR BRPI0517238-1A patent/BRPI0517238B1/pt active IP Right Grant
- 2005-10-12 RU RU2007119724/15A patent/RU2382647C2/ru active
- 2005-10-12 DE DE602005001833T patent/DE602005001833T2/de not_active Expired - Lifetime
- 2005-10-12 ES ES05077333T patent/ES2290844T3/es not_active Expired - Lifetime
- 2005-10-27 CA CA002520979A patent/CA2520979C/en not_active Expired - Lifetime
- 2005-10-27 PE PE2009001151A patent/PE20100089A1/es active IP Right Grant
- 2005-10-27 PE PE2005001260A patent/PE20060925A1/es not_active Application Discontinuation
- 2005-10-27 HN HN2005029978A patent/HN2005029978A/es unknown
- 2005-10-28 AR ARP050104538A patent/AR051653A1/es not_active Application Discontinuation
- 2005-10-28 PA PA20058650801A patent/PA8650801A1/es unknown
- 2005-10-28 JP JP2005315321A patent/JP4268163B2/ja not_active Expired - Lifetime
- 2005-10-28 MX MXPA05011650A patent/MXPA05011650A/es active IP Right Grant
- 2005-10-28 US US11/261,876 patent/US8895557B2/en active Active
- 2005-10-28 GT GT200500314A patent/GT200500314A/es unknown
- 2005-10-28 AU AU2005227421A patent/AU2005227421B2/en active Active
- 2005-10-28 UY UY29183A patent/UY29183A1/es not_active Application Discontinuation
- 2005-10-28 CN CNA2005101380761A patent/CN1823794A/zh active Pending
- 2005-10-28 MY MYPI20055116A patent/MY139049A/en unknown
- 2005-10-28 CN CN201010513008.XA patent/CN102018714B/zh not_active Expired - Lifetime
- 2005-10-28 SV SV2005002283A patent/SV2006002283A/es active IP Right Grant
- 2005-10-28 TW TW094137819A patent/TWI296523B/zh active
- 2005-10-30 JO JO2005167A patent/JO2464B1/en active
- 2005-12-10 UA UAA200705848A patent/UA91032C2/ru unknown
2007
- 2007-04-25 IL IL182776A patent/IL182776A/en active IP Right Grant
- 2007-04-26 ZA ZA200703450A patent/ZA200703450B/xx unknown
- 2007-05-29 NO NO20072713A patent/NO328035B1/no unknown
- 2007-08-30 HR HR20070374T patent/HRP20070374T3/xx unknown
- 2007-10-22 CY CY20071101361T patent/CY1107773T1/el unknown
2014
- 2014-10-09 US US14/510,819 patent/US10322183B2/en not_active Expired - Lifetime
2018
- 2018-02-19 AR ARP180100388A patent/AR110986A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20060094687A1 (en)	2006-05-04
DE602005001833T2 (de)	2008-04-17
RU2382647C2 (ru)	2010-02-27
SV2006002283A (es)	2006-07-20
EP1658848A1 (en)	2006-05-24
NO20072713L (no)	2007-07-19
UA91032C2 (en)	2010-06-25
CA2520979C (en)	2009-03-24
ZA200703450B (en)	2008-09-25
CN102018714A (zh)	2011-04-20
CY1107773T1 (el)	2013-06-19
HRP20070374T3 (en)	2007-10-31
ES2290844T3 (es)	2008-02-16
NZ554761A (en)	2010-01-29
GT200500314A (es)	2007-03-22
TW200621256A (en)	2006-07-01
PE20100089A1 (es)	2010-03-01
AU2005227421B2 (en)	2007-06-28
KR20070091121A (ko)	2007-09-07
NO328035B1 (no)	2009-11-10
JP2006124393A (ja)	2006-05-18
ATE368461T1 (de)	2007-08-15
MY139049A (en)	2009-08-28
RU2007119724A (ru)	2008-12-10
IL182776A0 (en)	2007-08-19
CN102018714B (zh)	2014-01-08
PT1658848E (pt)	2007-11-05
HK1091724A1 (en)	2007-01-26
JP4268163B2 (ja)	2009-05-27
MXPA05011650A (es)	2006-05-17
PE20060925A1 (es)	2006-10-23
KR101188691B1 (ko)	2012-10-09
US10322183B2 (en)	2019-06-18
IL182776A (en)	2010-06-30
AU2005227421A1 (en)	2006-05-18
AR051653A1 (es)	2007-01-31
DE602005001833D1 (de)	2007-09-13
SI1658848T1 (sl)	2007-12-31
RS50510B (sr)	2010-03-02
AR110986A2 (es)	2019-05-22
BRPI0517238B1 (pt)	2021-11-09
HN2005029978A (es)	2009-10-27
EP1658848B1 (en)	2007-08-01
JO2464B1 (en)	2009-01-20
WO2006046079A1 (en)	2006-05-04
DK1658848T3 (da)	2007-11-26
CA2520979A1 (en)	2006-02-15
CN1823794A (zh)	2006-08-30
US8895557B2 (en)	2014-11-25
US20150094313A1 (en)	2015-04-02
PA8650801A1 (es)	2006-09-22
BRPI0517238A (pt)	2008-10-07
TWI296523B (en)	2008-05-11
UY29183A1 (es)	2006-05-31

Publication	Publication Date	Title
ZA200703450B (en)	2008-09-25	Formulations comprising ecteinascidin and a disaccharide
IL180762A (en)	2015-06-30	Oligomer-insulin conjugates, formulations containing them and their use
GB0413730D0 (en)	2004-07-21	A pharmaceutical composition and its use
IL179795A0 (en)	2007-05-15	A pharmaceutical composition and its use
IL177566A0 (en)	2006-12-10	Pharmaceutical formulations
AP2006003768A0 (en)	2006-10-31	TetraazabenzoÄeÜazulene derivatives and analogs tehereof
GB0426301D0 (en)	2004-12-29	Pharmaceutical formulations
EP1841397A4 (en)	2010-01-27	TRICHOLOGY FORMULATIONS AND TREATMENTS
IL181300A0 (en)	2008-04-13	Photosensitizer formulations and uses thereof
IL182955A0 (en)	2007-08-19	Pharmaceutical compositions comprising a benzothiazol derivative and their use
IL178888A0 (en)	2007-03-08	Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
ZA200610032B (en)	2008-11-26	Oculoselective drugs and prodrugs
IL177826A0 (en)	2006-12-31	Oral matrix formulations comprising licarbazepine
GB0406048D0 (en)	2004-04-21	Drug formulations
EP1810976A4 (en)	2007-10-17	BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND THE USE THEREOF
ZA200703998B (en)	2008-11-26	Benzothiazole formulations and use thereof
GB0406014D0 (en)	2004-04-21	Pharmaceutical composition and use
IL179208A0 (en)	2007-03-08	Intereferon formulations
EP1841406A4 (en)	2008-06-25	METHOD AND FORMULATIONS
GB0414260D0 (en)	2004-07-28	Form and function fillings
EP1759703A4 (en)	2007-08-01	IMMUNOSTIMULATING AGENT AND INTERF ROGEN
GB0418932D0 (en)	2004-09-29	Helicopter-with tracked-launch and tunaround pad-vehicle design principles
IL165458A0 (en)	2006-01-15	And
GB0417226D0 (en)	2004-09-01	Formulations
GB0417248D0 (en)	2004-09-01	Formulations